225 related articles for article (PubMed ID: 18223695)
21. [Comparison of Acute Graft-Versus-Host Disease Mouse Models Established by TBI and BU/CY Conditioning Regimens].
Zhang Q; Lu YX; Xue C; Qu QY; Jiang YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1248-1254. PubMed ID: 35981393
[TBL] [Abstract][Full Text] [Related]
22. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
[No Abstract] [Full Text] [Related]
23. Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.
He X; Ye Y; Xu X; Wang J; Huang Y; Weng G; Zhang M; Guo K
Biomed Res Int; 2016; 2016():3071214. PubMed ID: 27843940
[TBL] [Abstract][Full Text] [Related]
24. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
25. Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.
Weng L; Dyson J; Dazzi F
Proc Natl Acad Sci U S A; 2007 May; 104(20):8415-20. PubMed ID: 17494756
[TBL] [Abstract][Full Text] [Related]
26. Enhancing effects of cyclosporin A on hematopoietic progenitors: possible role of CD8+ T cells as negative regulators.
Hashimoto F; Sugiura K; Inoue K; Ikehara S
Exp Hematol; 1994 Sep; 22(10):947-53. PubMed ID: 8088377
[TBL] [Abstract][Full Text] [Related]
27. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
McCune JS; Gooley T; Gibbs JP; Sanders JE; Petersdorf EW; Appelbaum FR; Anasetti C; Risler L; Sultan D; Slattery JT
Bone Marrow Transplant; 2002 Aug; 30(3):167-73. PubMed ID: 12189535
[TBL] [Abstract][Full Text] [Related]
28. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
Talamo G; Claxton DF; Dougherty DW; Ehmann CW; Sivik J; Drabick JJ; Rybka W
Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716
[TBL] [Abstract][Full Text] [Related]
29. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
30. Related donor hematopoietic stem cell transplantation for Fanconi anemia without radiation: a single center experience in Turkey.
Ertem M; Ileri T; Azik F; Uysal Z; Gozdasoglu S
Pediatr Transplant; 2009 Feb; 13(1):88-95. PubMed ID: 18433407
[TBL] [Abstract][Full Text] [Related]
31. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
Devine SM; Geller RB; Holland HK; Wingard JR; Saral R
Semin Oncol; 1993 Aug; 20(4 Suppl 4):56-63; quiz 64. PubMed ID: 8342077
[TBL] [Abstract][Full Text] [Related]
32. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
33. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
[TBL] [Abstract][Full Text] [Related]
35. The development of busulfan/cyclophosphamide preparative regimens.
Santos GW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
[TBL] [Abstract][Full Text] [Related]
36. Relevance of myeloablative conditioning in the engraftment of limiting numbers of normal and genetically marked lympho-hematopoietic stem cells.
Varas F; Bernad A; Almendral JM; Bueren JA
Bone Marrow Transplant; 1996 Nov; 18(5):981-9. PubMed ID: 8932855
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic intra-BM-BMT plus adult thymus transplantation from same donor has benefits for long-term survival even after sublethal irradiation or low-dose BM cell injection.
Nishida T; Hosaka N; Takaki T; Miyake T; Cui W; Inaba M; Kinoshita H; Matsuda T; Ikehara S
Bone Marrow Transplant; 2009 Jun; 43(11):829-37. PubMed ID: 19079314
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Schuler US; Ehrsam M; Schneider A; Schmidt H; Deeg J; Ehninger G
Bone Marrow Transplant; 1998 Aug; 22(3):241-4. PubMed ID: 9720736
[TBL] [Abstract][Full Text] [Related]
39. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
40. Phenotype of the engrafting stem cell in mice.
Quesenberry PJ; Becker P; Stewart FM
Stem Cells; 1998; 16 Suppl 1():33-5. PubMed ID: 11012146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
